These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26335771)

  • 41. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants.
    Suryadevara M
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S110-S114. PubMed ID: 38995085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
    Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.
    Mok H; Lee S; Utley TJ; Shepherd BE; Polosukhin VV; Collier ML; Davis NL; Johnston RE; Crowe JE
    J Virol; 2007 Dec; 81(24):13710-22. PubMed ID: 17928349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats.
    Joyce C; Scallan CD; Mateo R; Belshe RB; Tucker SN; Moore AC
    Vaccine; 2018 Jul; 36(29):4265-4277. PubMed ID: 29895499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.
    Hwang HS; Kwon YM; Lee JS; Yoo SE; Lee YN; Ko EJ; Kim MC; Cho MK; Lee YT; Jung YJ; Lee JY; Li JD; Kang SM
    Antiviral Res; 2014 Oct; 110():115-23. PubMed ID: 25110201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.
    Yang J; Ma C; Zhao Y; Fan A; Zou X; Pan Z
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
    Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
    Front Immunol; 2020; 11():1673. PubMed ID: 32849580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
    Rigter A; Widjaja I; Versantvoort H; Coenjaerts FE; van Roosmalen M; Leenhouts K; Rottier PJ; Haijema BJ; de Haan CA
    PLoS One; 2013; 8(8):e71072. PubMed ID: 23951084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus.
    Boukhvalova MS; Yim KC; Blanco J
    Antivir Chem Chemother; 2018; 26():2040206618770518. PubMed ID: 29768937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.
    Cullen LM; Blanco JC; Morrison TG
    J Transl Med; 2015 Nov; 13():350. PubMed ID: 26541285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The guinea pig as a model for the study of maternal immunization against respiratory syncytial virus infections in infancy.
    Buraphacheep W; Sullender WM
    J Infect Dis; 1997 Apr; 175(4):935-8. PubMed ID: 9086153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice.
    Noh Y; Shim BS; Cheon IS; Rho S; Kim HJ; Choi Y; Kang CY; Chang J; Song MK; Kim JO
    Viral Immunol; 2013 Aug; 26(4):268-76. PubMed ID: 23869549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.